Date: Tuesday, Apr. 5, 2016
Time: 11:15 a.m. CEST
Location: Room E5 Level 0, Kistamässan Convention Center, Stockholm, Sweden
Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic's proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. Symic has two clinical candidates, one in vascular injury and the other in osteoarthritis. In addition, Symic has several preclinical programs in oncology, fibrosis and CNS disorders.
Symic is based in San Francisco. For additional information, please visit the company's website at http://www.symic.bio or follow us on Twitter at www.twitter.com/symicbio and LinkedIn at www.linkedin.com/company/symic-bio/.
David Schull or Lena Evans
Russo Partners, LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-to-present-at-the-bio-europe-spring-conference-300241727.html